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No prospe&ive studies have compared sotalol 
and amiodarone durhtg electropharmacologic 
testing. The purpose of this prospe&ive, random- 
ized study was to compare the electrophysiologic 
effects of sotalol and amiodarone in patients 
with coronary artery disease and sustained 
monomorphic ventricular tachycardia (VT). 
Patients with coronary artery disease and sue 
tained monomorphic W inducible by programmed 
stimulation were randomly assigned to receive 
either sotalol (n = 17) or amiodarone (n q 17). 
The sotalol dose was titrated to 240 mg twice 
daily over 7 days. Amiodarone dosing consisted 
of 600 mg 3 times daily for 10 days. An electro- 
physiologic test was performed in the baseline 
state and at the end of the loading regimen. An 
adequate response was defined as the inability 
to induce Vc or the ability to induce only rela- 
tively slow hemodynamically stable V7. During 
the followup elechophysiologic test, 24% of 
patients taking sotalol and 41% of those taking 
amiodarone had an adequate response to thera- 
py (p = 0.30). Amiodarone lengthened the mean 
V7 cycle length to a greater degree than sotalol 
(28% vs 12%, p *O.Ol). There were no significant 
differences in the effects of sotalol and amio- 
darone on the ventricular effective refractory 
period. In patients with coronary artery disease, 
amiodarone and sotalol are similar in efficacy in 
thetreatmentofV7asassessed by electrophar 
macoldc testing. The effects of the 2 drugs on 
ventricular refractoriness are similar, but amio- 
darone slows VT to a greater extent than sotalol. 
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T he results of a large scale, prospective study sug- gested that sotalol may be more efficacious than several other antiarrhythmic agents in controlling 
ventricular tachycardia (VT).’ However, no prior studies 
have prospectively compared sotalol and amiodarone in 
the electrophysiology laboratory. The purpose of this 
study was to compare prospectively, in a randomized 
fashion, the electrophysiologic effects of sotalol and 
amiodarone in a homogenous group of patients with coro- 
nary artery disease and inducible sustained monomorphic 
VT undergoing electropharmacologic testing. 
METHODS 
Patients: The subjects in this study were 40 con- 
secutive patients (32 men and 8 women, mean age f SD 
64 f 9 years) with coronary artery disease and sustained 
monomorphic VT inducible by programmed ventricular 
stimulation. Mean left ventricular ejection fraction as 
measured by echocardiography or radionuclide ven- 
triculography was 0.34 + 0.09. Twenty-three patients 
presented with sustained VT, 13 patients presented with 
symptomatic, nonsustained VT, 2 patients presented with 
aborted sudden death, and 2 patients presented with syn- 
cope. Exclusion criteria included: (1) left ventricular 
ejection fraction ~0.20; (2) congestive heart failure unre- 
sponsive to conventional therapy; (3) pulmonary disease 
contraindicating the use of amiodarone; (4) liver disease 
or renal failure; (5) previous intolerance to B blockers; 
and (6) clinically significant sinus node dysfunction or 
atrioventricular block. There were no significant differ- 
ences in the clinical characteristics of the patients treat- 
ed with sotalol and amiodarone. 
Electrophysiologic testing: Informed, written con- 
sent was obtained from each patient under a protocol 
approved by the Human Research Committee at the Uni- 
versity of Michigan. Each patient underwent a baseline 
electrophysiologic test after discontinuation of all antiar- 
rhythmic agents for 25 half-lives. Quadripolar electrode 
catheters were inserted into a femoral vein and posi- 
tioned in the high right atrium, His bundle position, and 
right ventricular apex. Leads V,, I, II, and III, and the 
intracardiac electrograms were displayed on an oscillo- 
scope and recorded at a paper speed of 25 to 100 mm/s 
on a Mingograph 7 recorder (Siemens-Elema, Inc., Sol- 
na, Sweden). Pacing was performed at twice diastolic 
threshold with a pulse duration of 2 ms using a pro- 
grammable stimulator (Bloom Associates, Ltd., Read- 
ing, Pennsylvania). In all patients, the ventricular cap- 
ture threshold was <l mA. 
The AH and HV intervals were measured during atri- 
al pacing at a cycle length of 600 ms. The atrioventric- 
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ular block cycle length was determined by incremental 
atrial pacing in steps of 10 ms. The ventricular effective 
refractory period was measured at the right ventricular 
apex using a basic drive cycle length of 600 ms. The 
right atrium and ventricle were paced simultaneously 
using an 8-beat drive train and a 4-second intertrain 
pause. A l-minute conditioning train was used before 
the refractory periods were measured. The effective 
refractory period was measured by scanning diastole 
after each 8-beat drive train with a single ventricular 
extrastimulus. The coupling interval of the extrastimu- 
lus was shortened in 10 ms steps until there was loss of 
capture, and then lengthened in 2 ms steps until ven- 
tricular capture occurred. The effective refractory peri- 
od was defined as the longest coupling interval that did 
not result in ventricular capture. A prior study2 demon- 
strated that this technique for determination of the ven- 
tricular effective refractory period results in measure- 
ments that are reproducible to within 4 ms. 
The stimulation protocol used to induce VT has been 
described in detail previously.3 Programmed stimulation 
was initially performed at the right ventricular apex. One 
to 3 extrastimuli were delivered after an 8-beat drive train 
using a basic drive cycle length of 350 ms, then 400 and 
600 ms. If sustained VT was not induced, the stimula- 
tion protocol was repeated at the right ventricular septum 
or outflow tract. Whenever sustained VT was induced, 
a 12-lead electrocardiogram was recorded. In patients in 
whom multiple types of VT were induced, the VT that 
had the shortest cycle length was used for analysis. 
Sustained, monomorphic VT was defined as VT of 
uniform morphology lasting >30 seconds or requiring 
termination because of cardiovascular collapse. Hemo- 
dynamically stable VT was defined as VT associated 
with a systolic pressure >90 mm Hg and no symptoms 
of cerebral hypoperfusion. An adequate drug response 
was defined as the ability to induce only VT that had a 
cycle length of 2350 ms and was hemodynamically sta- 
ble,& or as the inability to induce VT7-9 The end points 
of the stimulation protocol were the induction of hemo- 
dynamically unstable sustained monomorphic VT, re- 
peated induction of only hemodynamically stable sus- 
tained monomorphic VT, or completion of the pacing 
protocol at 2 right ventricular sites. 
Drug therapy and electropharmacologic testi- 
Patients were randomly assigned to receive either sotalol 
or amiodarone. Both drugs were administered orally. 
Twenty-one patients assigned to receive sotalol were 
treated with 80 mg every 12 hours for 4 doses, 160 mg 
every 12 hours for 4 doses, then with 240 mg every 12 
hours for 5 doses, if tolerated. Nineteen patients assigned 
to receive amiodarone were treated with 600 mg every 
8 hours for 10 days. None of the patients were treated 
with any other antiarrhythmic drugs or p blockers. 
All patients underwent continuous, telemetric elec- 
trocardiographic monitoring and were questioned daily 
regarding the adverse effects of sotalol or amiodarone. 
Sotalol was discontinued in 1 patient due to heart fail- 
ure, in 2 patients due to symptomatic bradycardia, and 
in 1 patient because of torsades de pointes. The remain- 
ing 17 patients were able to tolerate a dosage of 240 mg 
of sotalol twice daily and underwent a follow-up elec- 
trophysiologic test after 7 days of therapy. Amiodarone 
was discontinued in 1 patient due to proarrhythmia and 
in 1 patient who developed an acute myocardial infarc- 
tion. One patient experienced nausea on day 3 of amio- 
darone therapy and the dose was reduced to 400 mg 3 
times daily. A follow-up electrophysiologic test was per- 
formed after 10 days of amiodarone therapy in 17 
patients. 
Statistical analysis: Values are expressed as mean 
+ SD. Comparisons of continuous variables were per- 
formed either using Student’s paired t test or by analy- 
sis of variance. Categorical variables were compared by 
chi-square analysis. A p value co.05 was considered sig- 
nificant. 
RESULTS 
Inducibility of ventricular tachycardla: All 34 pa- 
tients who successfully completed the loading regimens 
of sotalol and amiodarone had inducible, hemodynami- 
tally unstable sustained monomorphic VT in the base- 
line state. The mean VT cycle length was 268 f 32 ms. 
VT had a right bundle branch block configuration in 22 
patients and a left bundle branch block configuration in 
12 patients. VT was induced by triple extrastimuli in 23 
patients and by double extrastimuli in 11 patients. There 
were no significant baseline differences in VT charac- 
teristics between those taking sotalol and those taking 
amiodarone at the time of randomization. 
Sotalol was efficacious in 4 of 17 patients (24%), with 
efficacy manifest as complete suppression of inducible 
VT in each of the 4 patients. VT was induced by triple 
extrastimuli in 8 patients taking sotalol and by double 
extrastimuli in 5 taking sotalol. Amiodarone was effica- 
cious in 7 of 17 patients (41%). Among the 17 patients 
treated with amiodarone, VT was not inducible in 3 pa- 
tients (18%) and inducible but hemodynamically stable 
in 4 patients (24%). VT was induced by triple extrastim- 
uli in 10 patients taking amiodarone and by double 
extrastimuli in 4 taking amiodarone. The overall effica- 
cy of sotalol and amiodarone did not differ significantly 
(p = 0.30). 
Ventricular tachycardla cycle length: The mean 
VT cycle length was prolonged significantly both by 
sotalol (p ~0.01) and by amiodarone (p <O.OOl) com- 
pared with baseline. The magnitude of prolongation in 
the mean VT cycle length was 41 ms greater with amio- 
darone than with sotalol (p ~0.01). The mean VT cycle 
length in the 13 patients who still had inducible VT after 
treatment with sotalol increased by 12%, from 274 f 42 
to 306 f 33 ms (p <O.Ol), and none of the VTs were 
hemodynamically stable. In contrast, among the 14 
patients taking amiodarone who still had inducible VT, 
the mean VT cycle length increased by 28%, from 269 
+ 26 to 344 Z!Z 44 ms (p <O.OOl). Among the 4 patients 
who had inducible but hemodynamically stable VT after 
treatment with amiodarone, the mean VT cycle length 
increased by 47%, from 265 f 13 to 390 f 50 ms (p 
<O.ool). 
Ventricular effective refractory periods: Sotalol 
and amiodarone both significantly lengthened the ven- 
tricular effective refractory period (Figure 1). The mean 
ventricular effective refractory period in the sotalol group 
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increased by 19%, from 250 f 18 to 297 + 25 ms (p 
~0.001). Similarly, the ventricular effective refractory 
period in the amiodarone group increased by 15%, from 
262 + 26 to 301 + 33 ms (p <O.OOl). There was no sig- 
nificant difference in the magnitude of the effects of 
sotalol and amiodarone on the ventricular effective 
refractory period. 
In patients in whom there was an adequate drug 
response, the mean ventricular effective refractory peri- 
od in the sotalol group increased by 25%, from 253 f 
26 to 317 + 28 ms (p ~0.05) and the ventricular effec- 
tive refractory period in the amiodarone group increased 
by 22%, from 254 f 22 to 310 + 27 ms (p ~0.05). There 
was no significant difference in the effects of amiodarone 
and sotalol on the ventricular effective refractory period 
between the patients who responded to drug therapy and 
those who did not. 
Other electrophysiologw elects (Figure 1): Sota- 
101 lengthened the mean sinus cycle length by 42%, from 
786 + 104 to 1,113 f 123 ms (p <O.OOl), and amiodarone 
increased the mean sinus cycle length by 19%, from 821 
+ 188 to 975 f 167 ms (p ~0.01). The effect of sotalol on 
the sinus cycle length was greater than that of amiodarone 
(p <0.05). 
Sotalol lengthened the AH interval by 22%, from 108 
f 44 to 132 f 36 ms (p ~0.05) and amiodarone increased 
the mean AH interval by 35%, from 128 f 63 to 173 + 
78 ms (p ~0.01) during atria1 pacing at a cycle length of 
600 ms. The effects of the 2 drugs on AH interval did 
not differ significantly. 
Sotalol lengthened the mean atrioventricular block 
cycle length by 28%, from 362 + 51 to 462 + 66 ms (p 
<O.OOl) and amiodarone increased the mean atrioven- 
tricular block cycle length by 23%, from 454 + 132 to 
557 f 121 ms (p ~0.001). The effects of the 2 drugs on 
the atrioventricular block cycle length did not differ sig- 
nificantly. 
DISCUSSION 
Major findings: The major finding of this random- 
ized study is that sotalol and amiodarone were similar 
in efficacy for the control of VT as assessed by electro- 
physiologic testing in patients with coronary artery dis- 
ease. Although the 2 drugs were similar in their ability 
to suppress the induction of VT, amiodarone was more 
effective than sotalol in slowing the rate of VT in patients 
in whom VT remained inducible despite drug therapy. 
Effects of sotalol and amiodarone on ventricular 
tachycardia cycle length: The sotalol group had a 12% 
increase in the mean VT cycle length compared with 
28% in the amiodarone group. This greater increase in 
cycle length in the amiodarone group resulted in VT 
becoming hemodynamically stable in approximately 
25% of patients. In this subgroup of amiodarone patients, 
the mean VT cycle length increased by 43% compared 
with baseline. In contrast, induced VT did not become 
hemodynamically stable in any of the patients treated 
with sotalol who still had inducible VT 
The results of this study are in accord with the results 
of Nademanee et al,‘a who found that sotalol increased 
the mean VT cycle length by 20%. In addition, in a pre- 
vious study, amiodarone was reported to increase the 
mean VT cycle length by 33%,6 also in concert with the 
results of the present study. These findings suggest that 
amiodarone may slow conduction in the myocardium to 
a greater extent than sotalol. 
Ventricular effective refractory periods: In the 
present study, sotalol and amiodarone were found to 
lengthen the ventricular effective refractory period to a 
similar degree, and the extent of prolongation in the ven- 
tricular effective refractory period did not correlate with 
the ability of the drug to suppress the induction of VT 
This finding is consistent with the results of Kuchar et 
al,” who reported that changes in the ventricular effec- 
tive refractory period were not an indicator of the re- 
sponse to sotalol in patients with VT Additionally, in 
another study, the effects of amiodarone on the ventric- 
ular effective refractory period also were found not to 
correlate with its effects on the induction of VT.12 
Effects on sinus cycle length: The sinus cycle 
length was prolonged by a mean of almost 50% with 
sotalol compared with only approximately 20% with 
amiodarone. The greater depressant effect of sotalol on 
sinus node function was manifest by the occurrence of 
symptomatic bradycardia requiring discontinuation of 
therapy in 2 patients. This was the case despite the exclu- 
sion from this study of patients with clinical evidence of 
sinus node function. The greater degree of slowing of 
the sinus rate with sotalol is likely to be a reflection of 
its p adrenergic-blocking activity. 
Adverse drug effects: A significant degree of p- 
adrenergic blockade by sotalol was manifest not only by 
the occurrence of symptomatic bradycardia, but also by 
the occurrence of congestive heart failure in a patient 
being treated with sotalol. Although amiodarone also has 
p<o.o5 




RGURE 1. The electrophysiologic effects of sotalol (17 
patients) and amiodarone (17 patients). Vertical axis 
indicates the percent change compared with baseline 
for each of the variables shown. The values above each 
bar refer to the significance of the drug effect, and the 
values spannie adjacent bars refer to the comparison 
between sotalol and amiodarone. AH q interval rn88 
sured during atrial pacing at a cycle length of 600 ms; 
AVGCL q atrioventricular nodal block cycle length; HV = 
interval measured durhtg atrial pacing at a cycle length 
of 600 ms; SCL = sinus cycle length; VERP = ventricular 
effective refractory period measured at a basic drive 
train cycle length of 600 ms. 
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a clinically apparent sympatholytic effect, no adverse 
effects related to sympatholysis were noted in the pa- 
tients in this study treated with amiodarone. 
The overall dropout rates for sotalol and amiodarone 
during the loading period were 19% and ll%, respec- 
tively. In prior studies, the short-term incidence of adverse 
effects during treatment with sotalol and amiodarone have 
been reported to range from 13% to 16%,‘,13 and from 
0% to 5%,6,14 respectively. Therefore, amiodarone may 
be better tolerated than sotalol over the short term. How- 
ever, the long-term organ toxicity of amiodarone may 
counteract any short-term advantage over sotalol. 
Comparison with previous studies: The 24% effi- 
cacy of sotalol in the present study is at the lower end 
of the 24% to 67% range of efficacies reported in prior 
studies that have used electrophysiologic testing to eval- 
uate sotalol.U~15-20 This wide range in the efficacy of 
sotalol in the treatment of VT may be due to several fac- 
tors, including heterogeneous patient populations and 
different techniques for the assessment of drug efficacy. 
For example, in the Electrophysiology Study Versus 
Electrocardiographic Monitoring study,’ the efficacy of 
sotalol as judged by electrophysiologic testing was 35%, 
but in contrast to the present study, not all patients under- 
went programmed stimulation with triple extrastimuli. 
Two recent reports have demonstrated that drug efficacy 
may be overestimated when an incomplete stimulation 
protocol is used during electropharmacologic testing.*t,** 
The 41% efficacy of amiodarone in the present study 
is well within the 29% to 85% range of efficacies report- 
ed in prior studies. 6,23-26 Although the loading regimen 
for amiodarone has varied in these prior studies, a recent 
study demonstrated that the short-term electrophysio- 
logic effects of amiodarone may be independent of the 
total dosage of drug received over 10 days as long as a 
minimal dosage of 1,200 mg/day is given, as was the 
case in the present study and in most prior studies.6 
Aside from the present study, the only other random- 
ized comparison of sotalol and amiodarone was a study 
in which the efficacies of the 2 drugs were assessed in a 
heterogeneous group of patients solely by clinical follow- 
UP.*~ As in the present study, the 2 drugs did not differ 
significantly in efficacy. Treatment was judged to have 
been successful in 55% of patients treated with sotalol 
compared with 53% of patients treated with amiodarone. 
Study limitations: This study was limited to patients 
with coronary artery disease and sustained VT with pro- 
grammed stimulation. Therefore, the results may not 
necessarily apply to patients with other types of heart 
disease. 
A second potential limitation of this study is the rel- 
atively small sample size. Although the success rates of 
sotalol and amiodarone were not significantly different, 
there was a trend favoring amiodarone. It is possible that 
with a larger sample size, the difference in success rates 
between the 2 drugs would be significant. 
A third potential limitation of this study is the dose 
titration of sotalol to 480 mg/day. Young et a128 demon- 
strated higher efficacy with 640 mg/day of sotalol. It is 
possible that with a higher sotalol dosage, there may 
have been a clinical difference between the 2 drugs. 
However, the higher dosage may have resulted in a high- 
er dropout rate due to adverse effects. 
Clinical implications: This study has demonstrated 
that amiodarone and sotalol do not differ significantly in 
their ability to suppress the induction of sustained mono- 
morphic VT in patients with coronary artery disease. 
Therefore, in patients who may be appropriate candi- 
dates for treatment with a class III antiarrhythmic agent, 
the decision to use amiodarone or sotalol should be based 
more on a consideration of the potential adverse effects 
and toxicities of these 2 drugs, rather than on their rel- 
ative efficacy. The potential for torsades de pointes and 
side effects related to l3 blockade with sotalol must be 
weighed against the potential long-term organ toxicity 
of amiodarone. For example, in patients who have con- 
gestive heart failure, amiodarone may be the more appro- 
priate choice, while in younger patients who do not have 
severe left ventricular dysfunction, sotalol may be more 
appropriate. 
With the advent of nonthoracotomy lead systems and 
antitachycardia pacing algorithms, the implantable car- 
dioverter-defibrillator is playing an increasing role in the 
management of patients with sustained VT However, 
insertion of an implantable cardioverter-defibrillator may 
not always eliminate the need for antiarrhythmic drug 
therapy. Even when antiarrhythmic drugs are ineffective 
in suppressing episodes of VT, they may be helpful by 
slowing the rate of VT (e.g., to facilitate the use of anti- 
tachycardia pacing or to decrease the hemodynamic 
impact of the VT and the probability of syncope). The 
results of this study suggest that amiodarone may be 
preferable to sotalol when used in this context because 
it slows VT approximately twice as much as does sotalol. 
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